CASI Pharmaceuticals, Inc.

NasdaqCM:CASI 주식 보고서

시가총액: US$71.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CASI Pharmaceuticals 관리

관리 기준 확인 2/4

CASI Pharmaceuticals' CEO는 Wei-Wu He, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 는 $ 1.83M 가치에 해당하는 회사 주식의 5.29% 직접 소유합니다. 1.83M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 8.9 년입니다.

주요 정보

Wei-Wu He

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기5.3yrs
CEO 소유권5.3%
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간9yrs

최근 관리 업데이트

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

Feb 18
Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Jan 23
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

Dec 28
Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer

Dec 23

CEO 보상 분석

Wei-Wu He 의 보수는 CASI Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$30m

Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$10mUS$322k

-US$37m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$819kUS$578k

-US$48m

Sep 30 2020n/an/a

-US$47m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$9mUS$424k

-US$46m

Sep 30 2019n/an/a

-US$43m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$6mn/a

-US$27m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$781kn/a

-US$11m

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Wei-Wu 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: 회사가 수익성이 없는 동안 Wei-Wu 의 보상이 증가했습니다.

CEO

Wei-Wu He (59 yo)

5.3yrs

테뉴어

US$9,665,359

보상

Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...

리더십 팀

이름위치테뉴어보상소유권
Wei-Wu He
Chairman & CEO5.3yrsUS$9.67m5.29%
$ 3.8m
Wei Zhang
President4.8yrsUS$2.56m0.016%
$ 11.1k
Alexander A. Zukiwski
Executive VP & Chief Medical Officer7.3yrsUS$1.18m데이터 없음
Kun Qian
VP & Global Controller2.5yrs데이터 없음데이터 없음
Chunhua Wang
Chief Operating Officer6.3yrs데이터 없음데이터 없음
Wei Gao
General Counsel1.5yrs데이터 없음데이터 없음
James E. Goldschmidt
Chief Business Development Officerno data데이터 없음데이터 없음
Hai Huang
Global Chief Commercial Officer & GM of CASI Chinaless than a year데이터 없음데이터 없음
Amanda Cui
VP & Global Controllerno data데이터 없음데이터 없음

4.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: CASI 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Wei-Wu He
Chairman & CEO12.4yrsUS$9.67m5.29%
$ 3.8m
Sue Eckhardt
Member of Scientific Advisory Board18yrs데이터 없음데이터 없음
Y. Alexander Wu
Independent Director11.3yrsUS$150.50k데이터 없음
Thomas Folinsbee
Independent Directorno data데이터 없음데이터 없음
Ghassan Abou-Alfa
Member of Clinical Advisory Board9yrs데이터 없음데이터 없음
Zhenbo Su
Independent Director1.3yrs데이터 없음데이터 없음
Robert Mayer
Member of Clinical Advisory Board9yrs데이터 없음데이터 없음
Xuebo Zeng
Independent Director8.5yrs데이터 없음데이터 없음

9.0yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: CASI 의 이사회는 경험(평균 재직 기간 8.9 년)으로 간주됩니다.